Performance Measures of Effectiveness: Implementation and Findings

Table of Contents

Message from the Director

Executive Summary

List of Tables and Figures

1. Introduction
   • Bringing Accountability to Drug Policy
   • The First Crosscutting Model for Drug Policy
   • Organization of the Report
   • Acknowledgments

2. Progress Toward Achieving Performance Targets
   • The Problem of Lagging Indicators
   • Drug Use
   • Drug Availability
   • Drug Consequences
   • Milestones Met in 1998
   • Reporting on Progress in the 2000 PME System Report

3. PME System Accomplishments in 1998
   • Building Consensus
   • Managing Implementation of the Strategy
   • Linking Resources and Outcomes
   • Fostering Accountability and Change
   • A Complete Picture

4. Broadening the Base
   • Performance Partnerships
   • Performance Contracting
   • Building Incentives
   • Leveraging
   • Engaging the Public

5. Accomplishments and the Road Ahead
   • Progress Toward the Desired End-States
   • PME System Accomplishments
   • The Road Ahead

Appendix A: Strategic Goals and Objectives of the 1999 Strategy

Appendix B: Comparison of 1998 PME Targets with 1999 PME Targets

Appendix C: The Structure of the Strategy

Appendix D: Targets and Measures

• Terminology Key
• General Assumptions for Two or More Strategy Goals
• General Critical Factors -- Apply to Two or More Strategy Goals
• Goal 1
• Goal 2
• Goal 3
• Goal 4
• Goal 5

Appendix E: Congressional Performance Targets and the PME

Appendix F: Action Plans

Appendix G: PME Data Gap Analysis

Appendix H: Linking the Federal Drug Control Budget to the PME System

Appendix I: The ONDCP IMS

• Figure I-1 - Sample Milestone Measure Data Summary
• Figure I-2 - Sample Numerical Measure Data Summary

Appendix J: Acknowledgments